摘要
目的探讨SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效。方法选取201 1年2月1日一2015年10月1日我院行SOX和XELOX新辅助化疗的胃癌患者75例。分析两种方案临床分期、疗效评价、手术情况、术后病理、不良反应、生存分析等情况。结果 SOX和XELOX有效率分别为47.22%和41.03%。两组在CT疗效评价、有效率、疾病控制率方面比较,差异均不具有统计学意义(P>0.05);两组DFS、OS中位生存时间,差异均具有统计学意义(P<0.05)。结论 SOX和XELOX对进展期胃癌进行新辅助化疗均具有较高的安全性和有效性,XELOX远期疗效要优于SOX,改善患者预后。
Objective To investigate the clinical efficacy of SOX and XELOX in neoadjuvant chemo- therapy for advanced gastric carcinoma. Methods Seventy - five cases with advanced gastric carcinoma were se-lected from our hospital from Feb 1 ,2011 to Oct 1,2015. SOX and XELOX were used to these patients treatment. The relationship between SOX and XELOX with tumor stage,clinical curative effect evaluation,operation,postop-erative pathology, adverse reaction, survival analysis with advanced gastric carcinoma had been analyzed retrospec-tively. Results The efficacy of SOX and XELOX were 47. 22% ,41.03%. Compared with the two groups, the CT curative effect evaluation,effective rate,disease control rate had no significant differences（ P 〉0. 05） . The median survival time of DFS and OS were significant between the two groups （ P 〈 0. 05 ）. Conclusion The SOX and XELOX for neoadjuvant chemotherapy of advanced gastric carcinoma treatment is safety and effective, and the XELOX is better than SOX in terms of long - term effect, prognosis and clinical benefits.
出处
《实用肿瘤学杂志》
CAS
2017年第1期23-30,共8页
Practical Oncology Journal
基金
吴阶平基金科学技术部(320.6750.13105)
黑龙江省教育厅面上项目(12541458)
关键词
新辅助化疗
进展期胃癌
有效率
无病生存时间
总生存时间
Neoadjuvant chemotherapy
Advanced gastric carcinoma
Effective rate
Disease free surviv- al
Overall survival
